Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Tulin Budak-Alpdogan"'
Autor:
Omar S. Al-Odat, Weam Othman Elbezanti, Krishne Gowda, Sandeep K. Srivastava, Shantu G. Amin, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and almost all patients relapse. Poor patient outcomes demonstrate that myel
Externí odkaz:
https://doaj.org/article/63ddb4eafebe460cae46dd670075e26e
Autor:
Kuntal Bhowmick, Max von Suskil, Omar S. Al-Odat, Weam Othman Elbezanti, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Publikováno v:
Heliyon, Vol 10, Iss 12, Pp e33091- (2024)
Multiple Myeloma (MM) is a malignant expansion of plasma cells in the bone marrow (BM), resulting in a disease characterized by symptoms of end organ damage from light chain secretion, crowding of the BM, and bone lesions. Although the past two decad
Externí odkaz:
https://doaj.org/article/e2c7f16919af4116bc75f87862efdce9
Autor:
Weam Othman Elbezanti, Omar S. Al-Odat, Robert Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for myeloma recurrence is the persistent stem cell-like population. It has been demonstrated that
Externí odkaz:
https://doaj.org/article/6aace12e025c4c0bab03f2c7841776cc
Autor:
Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Publikováno v:
Pharmaceuticals, Vol 16, Iss 3, p 415 (2023)
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free surv
Externí odkaz:
https://doaj.org/article/ab2e1b0464064d68991d012df6bd5c4a
Autor:
Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane
Publikováno v:
Blood. 141:567-578
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f1e80634552189cee8742898d68b12
https://doi.org/10.1182/blood.2022017865
https://doi.org/10.1182/blood.2022017865
Autor:
Roland, Schwarting, Eric, Behling, Ashleigh, Allen, Vivian, Arguello-Guerra, Tulin, Budak-Alpdogan
Publikováno v:
Archives of Pathology & Laboratory Medicine. 146:415-432
Context.—In the early 1980s, a monoclonal antibody termed Ki-1 was developed against a cell line derived from a patient with Hodgkin lymphoma. This antibody detected a limited number of benign activated lymphocytes in lymphoid tissue, whereas in Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729ecf46b3cdd9656af71e896bebdad6
https://doi.org/10.5858/arpa.2021-0338-ra
https://doi.org/10.5858/arpa.2021-0338-ra
Autor:
Joseph R. Bertino, Dirk Moore, Daniel J. Medina, Anjali Warrier, Bobin Chen, Tulin Budak-Alpdogan
Supplementary Data from Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fa0ea446dfae30f91581cc1b1315122
https://doi.org/10.1158/1078-0432.22440066.v1
https://doi.org/10.1158/1078-0432.22440066.v1
Autor:
Nicole K. Schmalbach, Omar S. Al-Odat, Weam Othman Elbezanti, Gabriella Yao, Daniel A. Guirguis, Krishne Gowda, Shantu G Amin, Tulin Budak-Alpdogan, Subash C. Jonnalagadda, Manoj K. Pandey
Publikováno v:
Blood Cancer Discovery. 4:A01-A01
Acute myeloid leukemia (AML) is the most common leukemia in adult patients, with a 5-year survival rate of less than 30 percent. Therefore, more effective therapeutic strategies are required to prolong the survival of AML patients. Importantly, anti-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ea5678aeb65be9ff4e836c48a866833
https://doi.org/10.1158/2643-3249.aml23-a01
https://doi.org/10.1158/2643-3249.aml23-a01
Autor:
Omar S. Al Odat, Krishne Gowda, Shantu G. Amin, Tulin Budak- Alpdogan, Subash C. Jonnalagadda, Manoj K. Pandey
Publikováno v:
Cancer Research. 83:1748-1748
Recent advancements in multiple myeloma (MM) therapy have not changed the fact that it is incurable, and all patients experience relapse or become refractory. Thus, more effective treatments are needed to prolong the survival of MM patients. Anti-apo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::465f033a7233deec2091af7ec10af33d
https://doi.org/10.1158/1538-7445.am2023-1748
https://doi.org/10.1158/1538-7445.am2023-1748
Autor:
Omar S. Al-Odat, Daniel A. Guirguis, Nicole K. Schmalbach, Gabriella Yao, Tulin Budak-Alpdogan, Subash C. Jonnalagadda, Manoj K. Pandey
Publikováno v:
International Journal of Molecular Sciences. 24:644
Over the past two decades, the natural history of multiple myeloma (MM) has evolved dramatically, owing primarily to novel agents targeting MM in the bone marrow microenvironment (BMM) pathways. However, the mechanisms of resistance acquisition remai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51cfc1634d1b07458429da59dfac3596
https://doi.org/10.3390/ijms24010644
https://doi.org/10.3390/ijms24010644